Global Medical Sciences Group Looks At Benefits, Challenges And Risks Of Using RWD

The non-profit Council for International Organizations of Medical Sciences (CIOMS) has issued draft recommendations on using real-world evidence for the approval, use and reimbursement of medicinal products.

Background image of computer screen showing electronic medical records application with computer lab
RWD can complement data generated from randomized control trials • Source: Alamy

The increasing importance of real-world data (RWD) in clinical development and regulatory decision-making has prompted the Council for International Organizations of Medical Sciences to issue a new consensus report on this topic.

Key Takeaways
  • Real-world evidence (RWE) is well accepted by drug regulators for satisfying post-approval safety monitoring requirements, but there is now increasing willingness for its use to demonstrate drug effectiveness.

The draft CIOMS report – published on 6 June for stakeholder consultation – aims to inform discussions about the use...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from International

Australia Targets Clinical Trial Reform, AI Use And Drug Shortages In 12-Month Plan

 

Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.

Quotable: Top Experts On Policy Hot Topics

 

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Animal Testing Alternatives: US Pharmacopeia On Its Testing Transition

 

In this second of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet which animal testing models have alternative options and highlights where further investment and research is needed to develop appropriate alternatives.

EU Industry Proposes 3-Basket Strategy To Phase Out Animal Testing

 

A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.

More from Geography

PharmaMar Withdraws EU Aplidin Filing After Regulatory Rollercoaster

 

PharmaMar has voluntarily withdrawn its marketing authorization application for Aplidin to treat multiple myeloma in the EU – almost a decade after it first filed the drug for EU approval and following years of court proceedings.

Italy To Reward Locally Conducted R&D In Innovative Medicines Fund Revamp

 

Antibiotics that tackle antimicrobial resistance are to be automatically included in Italy’s Innovative Medicines Fund, which is designed to provide quick access to innovative medicines.

Real-Time Release Of CRLs Is US FDA’s Goal, Agency Leaders Affirm

 

The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.